Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 4:47 p.m.

    📋 Lexicon Pharmaceuticals, Inc. (LXRX) - Clinical Trial Update

    Filing Date: 2022-07-29

    Accepted: 2022-07-29 17:18:10

    Event Type: Clinical Trial Update

    Event Details:

    Lexicon Pharmaceuticals Inc. (LXRX) Announces Clinical Trial Update Lexicon Pharmaceuticals Inc. (LXRX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: sotagliflozin, managers
    • Diseases/Conditions: sotagliflozin in heart failure
    • Collaboration: Lexicon Pharmaceuticals, Inc.
      • targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933

    🔬 Clinical Development Pipeline (Lexicon Pharmaceuticals, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Ultomiris DRUG Preclinical Ultomiris-exposed Pregnant/ Postpartum ClinicalTrials.gov
    Best Supportive Care OTHER Phase PHASE3 Thrombotic Microangiopathy ClinicalTrials.gov
    Ravulizumab DRUG Phase PHASE3 Thrombotic Microangiopathy ClinicalTrials.gov
    Tarperprumig DRUG Phase PHASE2 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ClinicalTrials.gov
    ALXN2030 DRUG Phase PHASE2 Antibody-Mediated Rejection ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Lexicon Pharmaceuticals Inc.
    • CIK: 0001062822
    • Ticker Symbol: LXRX
    • Period End Date: 2022-07-27
    • Document Type: 8-K

Search

News categories